Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.1487
- Book/Share 37.7947
- PB 8.9493
- Debt/Equity 0.5906
- CurrentRatio 0.784
- ROIC 0.3934
- MktCap 1502977145956.646
- FreeCF/Share 13.9401
- PFCF 24.2459
- PE 13.542
- Debt/Assets 0.2059
- DivYield 0.0317
- ROE 0.7786
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
| Upgrade | NVO | Kepler | Hold | Buy | -- | -- | March 13, 2025 |
| Downgrade | NVO | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Initiation | NVO | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVO | Bernstein | Underperform | Market Perform | -- | -- | Jan. 6, 2025 |
News
Ozempic Maker Novo Nordisk to Cut 9,000 Jobs
Published: September 10, 2025 by: WSJ
Sentiment: Negative
The company downgraded its guidance for the second time in six weeks as it announced a restructuring plan.
Read More
Our H2 2025 Top Ideas
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
The US economy is showing signs of slowing, with the labor market cooling, consumer sentiment weak, Q3 GDP expected to slow to ~1.3%, and inflation still above the Fed's 2% target. Stagflation is now becoming a real risk. Markets are expensive; the S&P 500 is near all-time highs, and broad-market ETFs like VOO, QQQ, and VTI may only deliver modest returns over the next few years.
Read More
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: September 09, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Sept. 9, 2025 /PRNewswire/ -- The Law Offices of Frank R.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
Published: September 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers.
Read More
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Read More
Novo Nordisk: A Pharma Leader With Growth Potential And Portfolio-Defensive Appeal
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk is a strong buy, driven by its leading position in diabetes and obesity, robust fundamentals, and significant growth potential. The company's main revenue stream—GLP-1 drugs for diabetes and obesity—remains highly profitable, with substantial global market expansion opportunities ahead. Despite recent stock declines and high CapEx, Novo Nordisk's investments are strategic, but investors should monitor ROIC and competitive risks closely.
Read More
Novo Nordisk A/S Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Published: September 05, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Read More
Novo Nordisk A/S Class Action: The Gross Law Firm Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 – NVO
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Read More
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
NYSE: NVO DEADLINE REMINDER: Berger Montague Reminds Nordisk A/S (NYSE: NVO) Investors of Important Class Action Lawsuit Deadline
Published: September 04, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Sept. 4, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Novo Nordisk A/S.
Read More
Healthy Returns: Novo Nordisk's head of research and development previews the first-ever obesity pill
Published: September 03, 2025 by: CNBC
Sentiment: Positive
Novo Nordisk's Martin Holst Lange preveiwed the company's obesity pill, while OpenAI launches new initiative to speed up scientific discovery.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: September 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Read More
Should You Buy Novo Nordisk Stock Now or Wait?
Published: September 03, 2025 by: The Motley Fool
Sentiment: Neutral
In this video, I will talk about the recent updates regarding Novo Nordisk (NVO -0.16%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Read More
Investors who lost money on Novo Nordisk A/S (NVO) should contact Levi & Korsinsky about pending Class Action - NVO
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Read More
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: September 02, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Sept. 2, 2025 /PRNewswire/ -- The Law Offices of Frank R.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Read More
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
Read More
Wegovy trial result gives boost to Novo Nordisk amid U.S. market woes
Published: September 01, 2025 by: CNBC
Sentiment: Positive
Trial data released by Novo Nordisk showed a significant reduction in the risk of heart attack, stroke or death in certain patients on its blockbuster weight-loss treatment Wegovy, compared with drugs produced by the Danish firm's U.S. rival Eli Lilly. The companies are the leading players in the weight loss space, both grappling with challenges from copycat compounders and the race to develop next-generation treatments.
Read More
DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: August 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
Published: August 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline.
Read More
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: August 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk's Wegovy in MASH, According to Spherix Global Insights
Published: August 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
US Gastroenterologists and hepatologists highlight strong interest in Wegovy for addressing the metabolic roots of MASH. US Gastroenterologists and hepatologists highlight strong interest in Wegovy for addressing the metabolic roots of MASH.
Read More
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class Period"), of the important September 30, 2025 lead plaintiff deadline. So What: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Aug. 27, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S ("Novo" or the …
Read More
Form Health Selected for Novo Nordisk's NovoCare® Platform to Expand Access to Science-Based Obesity Care Across the United States
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Today, Form Health, the leading provider of science-based obesity and cardiometabolic care in the United States, announced its selection as a healthcare provider option on Novo Nordisk's NovoCare® platform. NovoCare® connects patients seeking treatment for chronic care with trusted healthcare providers, and Form Health's inclusion will expand access to high-quality, evidence-based care delivered by trained Obesity Medicine Clinicians and Registered Dietitians. The relat.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406